Tiziana Life Sciences (TLSA) Stock Price, News & Analysis

Company Overview

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biotechnology company developing therapies that modulate the immune system to treat neuroinflammatory and neurodegenerative diseases. The company’s lead product candidate is foralumab, a fully human monoclonal antibody designed to target the CD3 receptor on T cells and potentially reduce harmful immune activation.

Tiziana is primarily evaluating an intranasal formulation of foralumab in conditions involving inflammation of the central nervous system, including non-active secondary progressive multiple sclerosis and Alzheimer’s disease. The company has also investigated foralumab in other inflammatory and infectious-disease settings. Its intranasal delivery approach is intended to support localized effects in the central nervous system while avoiding the need for invasive administration.

Tiziana Life Sciences was founded in 2014 and has conducted research and clinical development activities in the United States and Europe. The company is led by Dr. Kunwar Shailubhai, who serves as chief executive officer and chief scientific officer. As a development-stage biotechnology company, Tiziana’s programs remain subject to clinical, regulatory and commercial uncertainties.

Key Stats

• Today's Range: $0.65 to $0.73
• 50-Day Range: $0.67 to $1.19
• 52-Week Range: $0.62 to $1.90
• Volume: 539,544 shs
• Average Volume: 665,695 shs
• Market Capitalization: $87.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Tiziana Life Sciences Stock Analysis - MarketRank™

Tiziana Life Sciences scored higher than 26% of companies evaluated by MarketBeat, and ranked 787th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Tiziana Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Tiziana Life Sciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.64% of the float of Tiziana Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Tiziana Life Sciences has a short interest ratio ("days to cover") of 4.27.

Change versus previous month

Short interest in Tiziana Life Sciences has recently increased by 5.69%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tiziana Life Sciences does not currently pay a dividend.

Dividend Growth

Tiziana Life Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.57

News Sentiment

Tiziana Life Sciences has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Tiziana Life Sciences this week, compared to 2 articles on an average week.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $318,909.00 in company stock, which represents 0.3631% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Tiziana Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $318,909.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

39.82% of the stock of Tiziana Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Tiziana Life Sciences has minimal institutional ownership at this time.

Company Calendar

• Today: 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TLSA
• CIK: 1723069
• Web: www.tizianalifesciences.com
• Phone: 44-20-7495-2379
• Fax: N/A
• Employees: 10
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 127,260,000
• Free Float: 76,584,000
• Market Cap: $87.82 million
• Optionable: Optionable
• Beta: 0.49